You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
SKF 77434 hydrobromide
Selective dopamine D1-like receptor partial agonist (IC50 values are 19.7 and 2425 nM for binding to D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.
Sold for research purposes under agreement from GlaxoSmithKline
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 376.29. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.66 mL||13.29 mL||26.58 mL|
|5 mM||0.53 mL||2.66 mL||5.32 mL|
|10 mM||0.27 mL||1.33 mL||2.66 mL|
|50 mM||0.05 mL||0.27 mL||0.53 mL|
References are publications that support the biological activity of the product.
Briggs et al (1991) Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393. Br.J.Pharmacol. 104 1038 PMID: 1687364
Meyer and Schults (1993) DA D1 receptor family agonists, SK&F38393, SK&F77434, and SK&F82958, differentially affect locomotor activities in rats. Pharmacol.Biochem.Behav. 46 269 PMID: 7903456
Neumeyer et al (1992) Stereoisomeric probes for the D1 DA receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue. J.Med.Chem. 35 1466 PMID: 1533424
If you know of a relevant reference for SKF 77434 hydrobromide, please let us know.
View Related Products by Product Action
Keywords: SKF 77434 hydrobromide, SKF 77434 hydrobromide supplier, Selective, D1-like, partial, agonists, Dopamine, Receptors, D5, dopaminergic, SKF77434, hydrobromide, GlaxoSmithKline, GSK, D1, and, 1662, Tocris Bioscience
Citations for SKF 77434 hydrobromide
Citations are publications that use Tocris products.
Currently there are no citations for SKF 77434 hydrobromide. Do you know of a great paper that uses SKF 77434 hydrobromide from Tocris? Please let us know.
Reviews for SKF 77434 hydrobromide
There are currently no reviews for this product. Be the first to review SKF 77434 hydrobromide and earn rewards!
Have you used SKF 77434 hydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.